Go Pro
→ Louis Navellier: My #1 AI stock for 2026 (name & ticker inside) (From InvestorPlace) (Ad)tc pixel Free RNTX Stock Alerts

Rein Therapeutics (RNTX) Financials

Rein Therapeutics logo
$0.86 -0.08 (-8.90%)
Closing price 07/16/2026 04:00 PM Eastern
Extended Trading
$0.88 +0.02 (+2.09%)
As of 07/16/2026 04:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Rein Therapeutics

Annual Income Statements for Rein Therapeutics

This table shows Rein Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -13 -18 -23 -32 -29 -21 -26 -27 -16 -63 -50
Consolidated Net Income / (Loss)		 -13 -18 -23 -32 -29 -21 -26 -27 -16 -63 -50
Net Income / (Loss) Continuing Operations		 -13 -18 -23 -32 -29 -21 -26 -27 -16 -63 -50
Total Pre-Tax Income 		-13 -18 -23 -32 -29 -21 -26 -27 -16 -64 -51
Total Operating Income		 -13 -18 -23 -32 -30 -20 -27 -28 -16 -65 -51
Total Gross Profit		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 13 18 23 32 30 20 27 28 16 65 51
Selling, General & Admin Expense		 5.06 7.89 8.77 13 12 9.33 9.60 9.68 11 14 11
Research & Development Expense		 7.83 10 14 18 18 11 17 18 3.99 14 11
Impairment Charge		 - - - - - - - - 0.00 37 29
Restructuring Charge		 - - - - - - - 0.00 0.93 0.00 0.00
Total Other Income / (Expense), net		 0.01 0.05 0.40 0.36 0.59 -0.66 0.44 0.32 0.54 0.69 0.05
Other Income / (Expense), net		 - - - - 0.59 -0.66 0.44 0.32 0.54 0.69 0.05
Income Tax Expense		 - - - - - - - - 0.00 -1.54 -0.71
Basic Earnings per Share		 ($32.31) ($42.35) ($3.04) ($2.14) ($1.20) ($0.61) ($5.89) ($6.02) ($3.42) ($3.51) ($1.96)
Weighted Average Basic Shares Outstanding		 400.71K 429.69K 7.44M 14.74M 24.54M 34.87M 4.44M 4.54M 4.60M 17.94M 25.44M
Diluted Earnings per Share		 ($32.31) ($42.35) ($3.04) ($2.14) ($1.20) ($0.61) ($5.89) ($6.02) ($3.42) ($3.51) ($1.96)
Weighted Average Diluted Shares Outstanding		 400.71K 429.69K 7.44M 14.74M 24.54M 34.87M 4.44M 4.54M 4.60M 17.94M 25.44M
Weighted Average Basic & Diluted Shares Outstanding		 400.71K 429.69K 7.44M 14.74M 24.54M 34.87M 88.81M 4.54M - 21.99M 28.04M
Cash Dividends to Common per Share		 - $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00

Quarterly Income Statements for Rein Therapeutics

This table shows Rein Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -1.83 -7.34 -7.11 -8.94 -5.85 -41 -5.50 -6.82 -5.58 -32 -5.84
Consolidated Net Income / (Loss)		 -1.83 -7.34 -7.11 -8.94 -5.85 -41 -5.50 -6.82 -5.58 -32 -5.84
Net Income / (Loss) Continuing Operations		 -1.83 -7.34 -7.11 -8.94 -5.85 -41 -5.50 -6.82 -5.58 -32 -5.84
Total Pre-Tax Income 		-1.83 -7.34 -7.11 -8.94 -5.85 -43 -5.50 -6.82 -5.58 -33 -5.84
Total Operating Income		 -1.98 -7.29 -7.21 -9.04 -6.07 -43 -5.61 -6.87 -5.49 -33 -5.23
Total Gross Profit		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Operating Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses		 1.98 7.29 7.21 9.04 6.07 43 5.61 6.87 5.49 33 5.23
Selling, General & Admin Expense		 1.96 5.33 3.74 5.30 2.35 2.48 2.56 2.58 3.81 1.96 2.16
Research & Development Expense		 0.02 1.97 3.46 3.74 3.72 3.32 3.05 4.29 1.68 2.00 3.07
Restructuring Charge		 0.01 -0.01 0.00 0.00 - - 0.00 0.00 - - 0.00
Total Other Income / (Expense), net		 0.16 -0.05 0.09 0.10 0.22 0.27 0.11 0.05 -0.09 -0.02 -0.61
Interest & Investment Income		 0.00 - 0.00 0.00 - - 0.00 0.00 - - 0.00
Other Income / (Expense), net		 0.16 -0.05 0.09 0.10 0.22 0.27 0.11 0.05 -0.09 -0.02 -0.61
Basic Earnings per Share		 ($0.40) ($1.60) ($0.86) ($0.45) ($0.27) ($2.28) ($0.25) ($0.28) ($0.21) ($1.22) ($0.19)
Weighted Average Basic Shares Outstanding		 4.54M 4.60M 8.30M 19.91M 21.66M 17.94M 21.92M 24.19M 26.36M 25.44M 30.35M
Diluted Earnings per Share		 ($0.40) ($1.60) ($0.86) ($0.45) ($0.27) ($2.28) ($0.25) ($0.28) ($0.21) ($1.22) ($0.19)
Weighted Average Diluted Shares Outstanding		 4.54M 4.60M 8.30M 19.91M 21.66M 17.94M 21.92M 24.19M 26.36M 25.44M 30.35M
Weighted Average Basic & Diluted Shares Outstanding		 4.54M 0.00 21.59M 21.67M 21.67M 21.99M 22.15M 23.31M 26.29M 28.04M 85.54M
Cash Dividends to Common per Share		 - - $0.00 - - - $0.00 - - - $0.00

Annual Cash Flow Statements for Rein Therapeutics

This table details how cash moves in and out of Rein Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 -2.44 17 -8.85 -0.72 -5.32 1.74 -4.01 1.59 12 -4.47 -9.65
Net Cash From Operating Activities		 -12 -15 -21 -28 -26 -20 -24 -25 -20 -22 -19
Net Cash From Continuing Operating Activities		 -12 -15 -21 -28 -26 -20 -24 -25 -20 -22 -19
Net Income / (Loss) Continuing Operations		 -13 -18 -23 -32 -29 -21 -26 -27 -16 -63 -50
Consolidated Net Income / (Loss)		 -13 -18 -23 -32 -29 -21 -26 -27 -16 -63 -50
Depreciation Expense		 0.33 0.23 0.13 0.22 0.16 0.16 0.12 0.17 0.12 0.06 0.00
Amortization Expense		 - - -0.15 -0.25 -0.23 -0.01 0.24 -0.21 0.03 0.00 0.00
Non-Cash Adjustments To Reconcile Net Income		 0.61 2.18 1.74 3.27 1.75 -3.23 1.74 1.95 1.09 38 31
Changes in Operating Assets and Liabilities, net		 0.24 0.70 0.36 0.39 1.22 3.75 0.31 0.55 -5.32 2.46 -0.87
Net Cash From Investing Activities		 11 -0.03 -39 25 -2.81 6.41 -36 26 16 0.00 0.00
Net Cash From Continuing Investing Activities		 11 -0.03 -39 25 -2.81 6.41 -36 26 16 0.00 0.00
Acquisitions		 - - - - - - - 0.00 -0.10 0.00 0.00
Purchase of Investments		 -2.37 -13 -71 -31 -27 -10 -74 -22 0.00 0.00 0.00
Sale of Property, Plant & Equipment		 - - - - 0.00 0.21 0.07 0.00 0.04 0.00 0.00
Sale and/or Maturity of Investments		 12 13 32 60 25 16 38 48 16 0.00 0.00
Net Cash From Financing Activities		 -1.36 32 51 2.52 24 16 56 0.00 16 18 9.76
Net Cash From Continuing Financing Activities		 -1.36 32 51 2.52 24 16 56 0.00 16 18 9.76
Issuance of Debt		 - - 52 2.47 - - - - - 0.00 2.85
Issuance of Common Equity		 - - - - 24 15 56 - 0.00 18 2.30
Other Financing Activities, net		 0.05 0.02 0.11 0.04 0.17 0.39 0.07 0.00 16 0.14 4.61
Other Net Changes in Cash		 - - - - - - - 0.00 -0.06 0.00 -0.04

Quarterly Cash Flow Statements for Rein Therapeutics

This table details how cash moves in and out of Rein Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 -1.10 5.24 -5.27 9.88 -4.27 -4.81 -5.44 -1.71 -1.67 -0.83 1.23
Net Cash From Operating Activities		 -1.64 -10 -5.27 -8.39 -3.82 -4.81 -6.18 -6.42 -3.55 -3.22 -3.42
Net Cash From Continuing Operating Activities		 -1.64 -10 -5.27 -8.39 -3.82 -4.81 -6.18 -6.42 -3.55 -3.22 -3.42
Net Income / (Loss) Continuing Operations		 -1.83 -7.34 -7.11 -8.94 -5.85 -41 -5.50 -6.82 -5.58 -32 -5.84
Consolidated Net Income / (Loss)		 -1.83 -7.34 -7.11 -8.94 -5.85 -41 -5.50 -6.82 -5.58 -32 -5.84
Depreciation Expense		 0.01 0.05 0.06 0.00 - - 0.00 0.00 - - 0.00
Amortization Expense		 -0.00 0.19 - - - - 0.00 - - - 0.62
Non-Cash Adjustments To Reconcile Net Income		 0.19 0.23 0.10 0.33 0.51 37 0.26 0.26 1.85 29 0.16
Changes in Operating Assets and Liabilities, net		 -0.01 -3.52 1.68 0.22 1.52 -0.96 -0.94 0.15 0.19 -0.26 1.64
Net Cash From Investing Activities		 0.54 -0.10 0.00 - - - 0.00 - - - 0.00
Net Cash From Continuing Investing Activities		 0.54 -0.10 0.00 - - - 0.00 - - - 0.00
Net Cash From Financing Activities		 - 16 0.00 18 -0.45 0.00 0.74 4.71 1.90 2.41 4.65
Net Cash From Continuing Financing Activities		 - 16 0.00 18 -0.45 0.00 0.74 4.71 1.90 2.41 4.65
Issuance of Debt		 - - - - - - 0.00 - - - 4.30
Issuance of Common Equity		 - - 0.00 18 -0.49 - 0.74 0.11 - 1.45 0.35
Other Financing Activities, net		 - 16 0.00 0.10 0.04 0.00 0.00 4.60 1.90 -1.90 0.00

Annual Balance Sheets for Rein Therapeutics

This table presents Rein Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 22 53 30 26 16 48 22 106 62 24
Total Current Assets		 21 52 22 20 16 48 22 18 14 4.33
Cash & Equivalents		 21 12 11 5.31 7.05 3.60 5.19 17 13 3.22
Prepaid Expenses		 0.33 1.00 1.06 1.25 1.93 2.22 0.61 0.88 0.79 1.11
Plant, Property, & Equipment, net		 0.11 0.15 7.29 0.30 0.02 0.13 0.07 0.02 0.00 0.00
Total Noncurrent Assets		 0.84 0.69 1.25 6.63 0.00 0.18 0.06 88 49 20
Goodwill		 - - - - - - 0.00 6.33 6.33 6.33
Intangible Assets		 - - - - - - 0.00 79 42 14
Other Noncurrent Operating Assets		 0.84 0.69 1.25 6.63 0.00 0.18 0.06 2.19 0.00 0.00
Total Liabilities & Shareholders' Equity		 22 53 30 26 16 48 22 106 62 24
Total Liabilities		 4.08 4.89 11 10 4.18 4.58 3.38 7.71 7.80 7.24
Total Current Liabilities		 4.07 4.89 5.37 5.84 3.96 4.51 3.38 4.39 5.75 6.18
Short-Term Debt		 - - - - - - - - - 0.00
Accounts Payable		 1.97 1.60 1.73 1.45 1.60 1.21 1.72 1.19 0.91 3.98
Accrued Expenses		 2.10 3.29 3.64 3.94 2.20 3.21 1.63 3.15 4.84 2.20
Total Noncurrent Liabilities		 0.01 0.00 5.34 4.59 0.22 0.07 0.00 3.33 2.05 1.06
Noncurrent Deferred & Payable Income Tax Liabilities		 - - - - - - 0.00 3.33 1.77 1.06
Other Noncurrent Operating Liabilities		 - - 5.34 4.59 0.22 0.07 - 0.00 0.28 0.00
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Redeemable Noncontrolling Interest		 130 - - - - - 0.00 91 45 45
Total Equity & Noncontrolling Interests		 -112 48 20 16 12 44 19 6.89 9.39 -28
Total Preferred & Common Equity		 -112 48 20 16 12 44 19 6.89 9.39 -28
Total Common Equity		 -112 48 20 16 12 44 19 6.89 9.39 -28
Common Stock		 2.54 185 188 214 231 289 291 295 361 373
Retained Earnings		 -114 -137 -168 -198 -219 -245 -273 -289 -351 -401
Accumulated Other Comprehensive Income / (Loss)		 - -0.03 -0.01 0.01 -0.00 -0.01 -0.05 -0.06 -0.02 -0.06

Quarterly Balance Sheets for Rein Therapeutics

This table presents Rein Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 13 99 109 104 58 57 54 26
Total Current Assets		 13 13 23 19 8.33 6.60 5.17 5.45
Cash & Equivalents		 12 12 22 18 7.43 5.72 4.05 4.45
Prepaid Expenses		 0.70 0.70 1.22 1.01 0.90 0.88 1.13 1.01
Plant, Property, & Equipment, net		 0.03 0.01 0.00 0.00 0.00 0.00 0.00 0.00
Total Noncurrent Assets		 0.00 86 86 86 49 51 49 21
Goodwill		 - 6.33 6.33 6.33 6.33 6.33 6.33 6.33
Intangible Assets		 - 79 79 79 42 42 42 14
Other Noncurrent Operating Assets		 0.00 0.89 0.71 0.00 0.77 2.35 0.00 1.01
Total Liabilities & Shareholders' Equity		 13 99 109 104 58 57 54 26
Total Liabilities		 1.62 7.86 8.38 8.99 7.75 9.47 7.52 15
Total Current Liabilities		 1.62 4.53 4.94 5.66 5.98 7.69 5.74 14
Short-Term Debt		 - - - - - - - 4.92
Accounts Payable		 0.48 2.16 0.78 1.08 1.15 6.03 4.12 6.26
Accrued Expenses		 1.14 2.38 4.16 4.58 4.83 1.67 1.62 2.45
Total Noncurrent Liabilities		 0.00 3.33 3.44 3.33 1.77 1.77 1.77 1.06
Noncurrent Deferred & Payable Income Tax Liabilities		 - 3.33 3.33 3.33 1.77 1.77 1.77 1.06
Other Noncurrent Operating Liabilities		 0.00 0.00 0.12 0.00 0.00 0.00 0.00 0.00
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Redeemable Noncontrolling Interest		 - 47 45 45 45 45 45 45
Total Equity & Noncontrolling Interests		 11 45 56 50 4.87 3.01 1.19 -33
Total Preferred & Common Equity		 11 45 56 50 4.87 3.01 1.19 -33
Total Common Equity		 11 45 56 50 4.87 3.01 1.19 -33
Common Stock		 292 340 361 361 362 367 371 374
Retained Earnings		 -281 -296 -305 -310 -357 -364 -369 -407
Accumulated Other Comprehensive Income / (Loss)		 0.00 -0.06 -0.02 -0.03 -0.03 -0.04 -0.04 -0.06

Annual Metrics And Ratios for Rein Therapeutics

This table displays calculated financial ratios and metrics derived from Rein Therapeutics' official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 4,919,615.00 4,919,615.00 14,718,787.00 14,748,475.00 27,810,358.00 40,684,649.00 90,573,597.00 90,823,597.00 4,541,167.00 21,665,941.00 26,286,382.00
DEI Adjusted Shares Outstanding		 245,981.00 245,981.00 735,939.00 737,424.00 1,390,518.00 2,034,232.00 4,528,680.00 4,541,180.00 4,541,167.00 21,665,941.00 26,286,382.00
DEI Earnings Per Adjusted Shares Outstanding		 -52.64 -73.98 -30.77 -42.78 -21.12 -10.40 -5.78 -6.02 -3.46 -2.90 -1.90
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 0.00% -42.74% -28.40% -38.67% 7.80% 28.67% -22.85% -6.07% 43.07% -313.09% 21.41%
EBIT Growth		 0.00% -40.94% -26.63% -38.66% 7.94% 27.96% -23.67% -4.45% 42.43% -309.53% 21.49%
NOPAT Growth		 0.00% -40.94% -26.63% -38.66% 6.10% 31.58% -29.81% -3.92% 41.13% -300.05% 22.24%
Net Income Growth		 0.00% -40.73% -24.73% -39.56% 6.90% 27.96% -23.67% -4.45% 42.43% -299.71% 20.69%
EPS Growth		 0.00% -31.07% 92.82% 29.61% 43.93% 49.17% -23.67% -2.21% 43.19% -2.63% 44.16%
Operating Cash Flow Growth		 0.00% -28.22% -36.75% -36.02% 5.20% 22.66% -16.01% -4.68% 20.34% -12.54% 13.14%
Free Cash Flow Firm Growth		 0.00% 0.00% -59.96% -52.89% 18.22% 27.57% -30.90% 0.23% -406.30% 93.53% -23.94%
Invested Capital Growth		 0.00% 0.00% -8.64% 63.19% -101.34% 0.84% 8.14% -28.72% 3,161.99% -48.71% -67.00%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 0.00% 0.00% 0.00% 0.18% 0.86% 10.64% -9.02% 7.53% -20.51% -120.98% 16.29%
EBIT Q/Q Growth		 0.00% 0.00% 0.00% 0.18% 0.74% 10.55% -9.10% 8.00% -23.29% -120.33% 16.29%
NOPAT Q/Q Growth		 0.00% 0.00% 0.00% 0.18% -1.24% 13.35% -10.94% 7.10% -18.90% -119.94% 16.68%
Net Income Q/Q Growth		 0.00% 0.00% 0.00% -0.54% -0.69% 9.57% -7.40% 7.61% -21.58% -115.05% 15.31%
EPS Q/Q Growth		 0.00% 0.00% 0.00% -112.36% 20.53% -3.39% -7.40% 7.53% -20.00% -160.00% 12.11%
Operating Cash Flow Q/Q Growth		 0.00% 0.00% -8.48% -3.04% 1.33% 7.31% -7.06% 6.91% -43.27% 20.02% 7.60%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 5.01% 13.66% -15.18% 6.99% -726.61% 93.80% -6.91%
Invested Capital Q/Q Growth		 0.00% 0.00% 0.00% 42.24% -27.40% -32.46% 4.38% 5.77% 9,135.60% -46.45% -67.48%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 97.60% 98.59%
Interest Burden Percent		 99.90% 99.75% 98.24% 98.89% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 0.00% -101.03% -68.77% -93.62% -164.77% -150.00% -93.33% -87.42% -26.91% -82.37% -139.87%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -117.34% -10.04% -27.59%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 0.00% 629.65% 66.97% -93.62% -164.77% -150.00% -93.33% -87.42% -5.87% -8.78% 36.68%
Return on Equity Simple (ROE_SIMPLE)		 0.00% 16.21% -47.29% -160.95% -183.01% -173.96% -59.59% -146.75% -228.43% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -9.02 -13 -16 -22 -21 -14 -19 -19 -11 -46 -35
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 0.00% -52.12% -18.16% -25.76% -43.05% -41.65% -24.99% -23.73% -22.48% -114.59% -179.47%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - - -165.43% -485.55% 126.19%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -13 -18 -23 -32 -29 -21 -26 -27 -16 -64 -51
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -13 -18 -23 -32 -29 -21 -26 -27 -16 -64 -51
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 3.25 0.63 0.99 3.48 1.16 0.58 2.01 5.31 0.00
Price to Tangible Book Value (P/TBV)		 0.00 0.00 3.25 0.63 0.99 3.48 1.16 0.58 0.00 0.00 0.00
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.09 1.97 5.27
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 0.00 -1.16 -1.09 -1.06 -1.09 -1.16 -1.08 -1.08 -0.33 -0.20 -0.23
Leverage Ratio		 0.00 1.23 1.14 1.23 1.59 1.52 1.16 1.13 1.09 1.10 1.21
Compound Leverage Factor		 0.00 1.22 1.12 1.22 1.59 1.52 1.16 1.13 1.09 1.10 1.21
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 723.26% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 92.99% 82.74% 266.02%
Common Equity to Total Capital		 0.00% -623.26% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 7.01% 17.26% -166.02%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 0.00 0.00 15.02 -9.91 -12.60 -16.08 -1.10 -18.54 -3.07 -7.34 -27.73
Noncontrolling Interest Sharing Ratio		 0.00% 723.26% 197.37% 0.00% 0.00% 0.00% 0.00% 0.00% 78.18% 89.34% 126.22%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 0.00 5.18 10.60 4.05 3.35 4.12 10.69 6.46 4.17 2.38 0.70
Quick Ratio		 0.00 5.09 10.38 3.85 3.13 3.49 10.19 6.28 3.95 2.24 0.52
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -9.92 -16 -24 -20 -14 -19 -19 -95 -6.15 -7.62
Operating Cash Flow to CapEx		 -12,457.45% 0.00% -14,458.45% -631.38% -17,532.45% 0.00% -26,103.30% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 0.00 -2.80 -3.04 -1.12 -2.26 -2.24 -2.05 -2.64 81 42 14
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 0.00 -2.80 -0.24 1.92 -1.14 0.02 0.18 -0.59 84 -39 -28
Enterprise Value (EV)		 0.00 0.00 104 -8.33 -2.37 28 5.03 -11 88 82 72
Market Capitalization		 0.00 0.00 155 12 16 42 51 11 14 50 30
Book Value per Share		 $0.00 ($22.73) $3.25 $1.33 $0.58 $0.30 $0.48 $0.21 $1.52 $0.43 ($1.07)
Tangible Book Value per Share		 $0.00 ($22.73) $3.25 $1.33 $0.58 $0.30 $0.48 $0.21 ($17.32) ($1.81) ($1.82)
Total Capital		 0.00 18 48 20 16 12 44 19 98 54 17
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 0.00 -21 -51 -21 -18 -14 -46 -21 -17 -13 -3.22
Capital Expenditures (CapEx)		 0.09 0.00 0.14 4.42 0.15 -0.20 0.09 0.00 -0.04 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.00 -3.74 -3.89 -4.32 -4.59 -2.03 -2.29 -2.78 -3.46 -4.96 -5.07
Debt-free Net Working Capital (DFNWC)		 0.00 17 47 16 14 12 44 18 14 7.91 -1.85
Net Working Capital (NWC)		 0.00 17 47 16 14 12 44 18 14 7.91 -1.85
Net Nonoperating Expense (NNE)		 3.85 5.40 6.50 9.22 8.40 6.81 7.54 7.98 4.34 17 14
Net Nonoperating Obligations (NNO)		 0.00 -21 -51 -21 -18 -14 -46 -21 -17 -13 -3.22
Total Depreciation and Amortization (D&A)		 0.33 0.23 -0.02 -0.04 -0.08 0.15 0.36 -0.04 0.15 0.06 0.00
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($646.20) ($847.00) ($60.80) ($42.80) ($24.00) $0.00 ($5.80) ($6.02) ($3.42) ($3.51) ($1.96)
Adjusted Weighted Average Basic Shares Outstanding		 20.04K 21.48K 736.72K 743.75K 1.39M 0.00 4.53M 4.54M 4.60M 17.94M 25.44M
Adjusted Diluted Earnings per Share		 ($646.20) ($847.00) ($60.80) ($42.80) ($24.00) $0.00 ($5.80) ($6.02) ($3.42) ($3.51) ($1.96)
Adjusted Weighted Average Diluted Shares Outstanding		 20.04K 21.48K 736.72K 743.75K 1.39M 0.00 4.53M 4.54M 4.60M 17.94M 25.44M
Adjusted Basic & Diluted Earnings per Share		 ($646.20) ($847.00) ($60.80) ($42.80) ($24.00) $0.00 ($5.80) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 20.04K 21.48K 372.15K 736.91K 1.23M 0.00 4.44M 4.54M 0.00 21.99M 28.04M
Normalized Net Operating Profit after Tax (NOPAT)		 -9.02 -13 -16 -22 -21 -14 -19 -19 -11 -20 -15
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 -10.25% -0.99% -10.19% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Rein Therapeutics

This table displays calculated financial ratios and metrics derived from Rein Therapeutics' official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 4,541,167.00 4,541,167.00 4,541,167.00 21,589,576.00 21,665,799.00 21,665,941.00 21,992,387.00 22,153,736.00 23,305,108.00 26,286,382.00 28,039,032.00
DEI Adjusted Shares Outstanding		 4,541,167.00 4,541,167.00 4,541,167.00 21,589,576.00 21,665,799.00 21,665,941.00 21,992,387.00 22,153,736.00 23,305,108.00 26,286,382.00 28,039,032.00
DEI Earnings Per Adjusted Shares Outstanding		 -0.40 -1.62 -1.57 -0.41 -0.27 -1.89 -0.25 -0.31 -0.24 -1.22 -0.21
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 72.06% -59.64% -45.77% -389.22% -221.97% -499.03% 22.02% 23.69% 4.55% 23.15% 5.20%
EBIT Growth		 71.80% -68.06% -48.84% -400.39% -220.03% -479.44% 22.66% 23.71% 4.55% 23.15% -6.13%
NOPAT Growth		 69.41% -55.01% -43.78% -353.77% -206.15% -487.06% 22.15% 23.99% 9.54% 23.69% 6.76%
Net Income Growth		 71.31% -61.40% -48.84% -400.39% -220.03% -458.40% 22.66% 23.71% 4.55% 22.00% -6.13%
EPS Growth		 71.43% -60.00% 18.10% -15.38% 32.50% -42.50% 70.93% 37.78% 22.22% 46.49% 24.00%
Operating Cash Flow Growth		 76.47% -135.68% -13.09% -169.22% -132.87% 53.69% -17.15% 23.50% 7.10% 33.08% 44.55%
Free Cash Flow Firm Growth		 14.98% -3,182.85% -2,768.21% -1,913.89% -2,407.53% 110.68% 137.90% 137.05% 138.17% -47.62% -18.76%
Invested Capital Growth		 68.07% 3,161.99% 3,305.30% 8,915.94% 8,755.69% -48.71% -46.45% -46.52% -45.66% -67.00% -71.57%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 0.60% -290.91% 0.63% -26.71% 34.58% -627.30% 87.06% -24.00% 18.18% -485.54% 84.04%
EBIT Q/Q Growth		 -2.24% -301.70% 3.08% -25.71% 34.61% -627.30% 87.06% -24.01% 18.19% -485.54% 82.14%
NOPAT Q/Q Growth		 0.45% -267.62% 1.17% -25.45% 32.84% -604.94% 86.89% -22.50% 20.07% -494.67% 83.99%
Net Income Q/Q Growth		 -2.24% -301.70% 3.08% -25.71% 34.61% -600.89% 86.58% -24.01% 18.19% -472.78% 81.74%
EPS Q/Q Growth		 -2.56% -300.00% 46.25% 47.67% 40.00% -744.44% 89.04% -12.00% 25.00% -480.95% 84.43%
Operating Cash Flow Q/Q Growth		 47.37% -533.60% 49.27% -59.15% 54.48% -26.00% -28.33% -3.94% 44.72% 9.24% -6.34%
Free Cash Flow Firm Q/Q Growth		 23.04% -2,589.61% 2.17% 0.55% 4.17% 111.46% 247.15% -2.77% -1.28% -84.28% 438.44%
Invested Capital Q/Q Growth		 0.11% 9,135.60% -2.09% -0.24% -1.93% -46.45% 2.23% -0.38% -0.35% -67.48% -11.92%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 96.37% 100.00% 100.00% 100.00% 97.82% 100.00%
Interest Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -76.36% -26.91% -34.21% -44.32% -54.95% -82.37% -86.78% -79.38% -83.28% -139.87% -163.36%
Cash Return on Invested Capital (CROIC)		 0.00% -117.34% -119.43% -123.72% -127.88% -10.04% -12.56% -10.14% -11.91% -27.59% -17.59%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -76.36% -5.87% -19.12% -26.79% -31.71% -8.78% -30.49% -31.44% -30.27% 36.68% 75.85%
Return on Equity Simple (ROE_SIMPLE)		 -115.56% 0.00% -40.37% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -1.39 -5.10 -5.04 -6.33 -4.25 -30 -3.93 -4.81 -3.84 -23 -3.66
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -2.33% -11.58% -14.37% -14.68% -10.73% -72.99% -16.15% -14.55% -15.99% -113.26% -62.65%
Return On Investment Capital (ROIC_SIMPLE)		 - -74.10% -11.27% -11.30% -8.46% -319.14% -80.56% -159.90% -324.42% 81.39% 12.85%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -1.83 -7.34 -7.11 -8.94 -5.85 -43 -5.50 -6.82 -5.58 -33 -5.84
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -1.82 -7.10 -7.05 -8.94 -5.85 -43 -5.50 -6.82 -5.58 -33 -5.22
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.62 2.01 0.67 1.07 1.53 5.31 7.87 10.31 22.52 0.00 0.00
Price to Tangible Book Value (P/TBV)		 0.62 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 1.09 0.82 1.05 1.34 1.97 1.79 1.66 1.61 5.27 6.79
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.42
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.11 -0.33 -0.27 -0.31 -0.28 -0.20 -0.14 -0.19 -0.15 -0.23 -0.11
Leverage Ratio		 1.18 1.09 1.10 1.08 1.10 1.10 1.11 1.12 1.12 1.21 1.37
Compound Leverage Factor		 1.18 1.09 1.10 1.08 1.10 1.10 1.11 1.12 1.12 1.21 1.37
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 29.81%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 29.81%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 92.99% 51.00% 44.55% 47.26% 82.74% 90.23% 93.74% 97.43% 266.02% 272.53%
Common Equity to Total Capital		 100.00% 7.01% 49.00% 55.45% 52.74% 17.26% 9.77% 6.27% 2.57% -166.02% -202.34%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.10
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.01
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.14
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.01
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 -27.58 -2.80 -2.01 0.31 0.92 -6.18 -5.97 -7.31 -7.85 -25.28 -21.30
Noncontrolling Interest Sharing Ratio		 0.00% 78.18% 44.11% 39.54% 42.29% 89.34% 64.86% 60.40% 63.65% 126.22% 146.43%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 7.88 4.17 2.82 4.69 3.30 2.38 1.39 0.86 0.90 0.70 0.40
Quick Ratio		 7.43 3.95 2.66 4.44 3.12 2.24 1.24 0.74 0.70 0.52 0.33
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -3.30 -89 -87 -86 -83 9.47 33 32 32 4.96 27
Operating Cash Flow to CapEx		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -0.90 81 79 79 78 42 42 42 42 14 12
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 1.91 84 82 80 78 -39 -37 -37 -35 -28 -30
Enterprise Value (EV)		 -5.19 88 65 83 104 82 76 70 68 72 82
Market Capitalization		 6.90 14 30 60 77 50 38 31 27 30 36
Book Value per Share		 $2.47 $1.52 $9.85 $2.59 $2.32 $0.43 $0.23 $0.14 $0.05 ($1.07) ($1.19)
Tangible Book Value per Share		 $2.47 ($17.32) ($8.98) ($1.37) ($1.63) ($1.81) ($2.02) ($2.05) ($2.03) ($1.82) ($1.90)
Total Capital		 11 98 91 101 95 54 50 48 46 17 17
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 4.92
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -12 -17 -12 -22 -18 -13 -7.43 -5.72 -4.05 -3.22 0.48
Capital Expenditures (CapEx)		 -0.04 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -0.93 -3.46 -3.84 -3.72 -4.65 -4.96 -5.07 -6.81 -4.62 -5.07 -7.71
Debt-free Net Working Capital (DFNWC)		 11 14 8.23 18 13 7.91 2.35 -1.09 -0.57 -1.85 -3.26
Net Working Capital (NWC)		 11 14 8.23 18 13 7.91 2.35 -1.09 -0.57 -1.85 -8.18
Net Nonoperating Expense (NNE)		 0.44 2.24 2.07 2.61 1.60 11 1.57 2.01 1.74 9.11 2.18
Net Nonoperating Obligations (NNO)		 -12 -17 -12 -22 -18 -13 -7.43 -5.72 -4.05 -3.22 0.48
Total Depreciation and Amortization (D&A)		 0.01 0.24 0.06 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.62
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.40) ($1.60) ($0.86) ($0.45) ($0.27) ($2.28) ($0.25) ($0.28) ($0.21) ($1.22) ($0.19)
Adjusted Weighted Average Basic Shares Outstanding		 4.54M 4.60M 8.30M 19.91M 21.66M 17.94M 21.92M 24.19M 26.36M 25.44M 30.35M
Adjusted Diluted Earnings per Share		 ($0.40) ($1.60) ($0.86) ($0.45) ($0.27) ($2.28) ($0.25) ($0.28) ($0.21) ($1.22) ($0.19)
Adjusted Weighted Average Diluted Shares Outstanding		 4.54M 4.60M 8.30M 19.91M 21.66M 17.94M 21.92M 24.19M 26.36M 25.44M 30.35M
Adjusted Basic & Diluted Earnings per Share		 $0.00 ($1.60) $0.00 $0.00 $0.00 ($2.28) $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 4.54M 0.00 21.59M 21.67M 21.67M 21.99M 22.15M 23.31M 26.29M 28.04M 85.54M
Normalized Net Operating Profit after Tax (NOPAT)		 -1.38 -5.11 -5.04 -6.33 -4.25 -30 -3.93 -4.81 -3.84 -23 -3.66
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Rein Therapeutics (NASDAQ: RNTX) continues to look like a development-stage biotech with no product revenue, significant operating losses, and a balance sheet that has improved in terms of liquidity but remains heavily dependent on financing. Over the last several years, the company has steadily increased spending while burning cash, though it also ended Q1 2026 with a somewhat stronger cash position than it held at the end of 2025.

Key takeaways from the last four years:

  • Cash and equivalents improved to $4.45 million in Q1 2026 from $4.05 million in Q3 2025 and $3.01 million in Q2 2025, showing a modest rebound in liquidity.
  • Q1 2026 operating cash burn improved sharply year over year, with cash used in operations at -$3.42 million versus -$6.42 million in Q2 2025 and -$3.55 million in Q3 2025.
  • The company raised $4.30 million of debt and $354,000 of common equity in Q1 2026, helping offset operating losses and lift cash.
  • Operating expenses in Q1 2026 were lower than the prior quarter, with SG&A of $2.16 million and R&D of $3.07 million, down from the much larger loss profile seen in Q4 2025.
  • Compared with the end of 2024, the company has dramatically reduced its operating cash outflows and appears to be managing spending more tightly.
  • The balance sheet still carries a very large redeemable noncontrolling interest of $45.0 million, which is a major claim on the enterprise structure.
  • Intangible assets remain substantial at $13.5 million in Q1 2026, but they are far below the $42.2 million reported through much of 2024 and 2025, suggesting prior asset reclassification or write-down activity.
  • The company had no revenue in every quarter provided, so the investment case still rests entirely on clinical, regulatory, or financing progress.
  • Q1 2026 net loss was still large at -$5.84 million, or -$0.19 per share, showing the business remains far from profitability.
  • Total common equity was still negative at -$33.4 million in Q1 2026, indicating a weak residual equity position for common shareholders.
  • Total liabilities rose to $14.70 million in Q1 2026 from $9.47 million in Q2 2025, reflecting added leverage and financial obligations.
  • The company has a long history of steep quarterly losses, including a $31.97 million net loss in Q4 2025 and $40.98 million in Q4 2024.
  • Dilution remains a concern: weighted average shares outstanding have generally trended higher over time, reflecting repeated financing needs.

Trend summary: Rein Therapeutics has made progress in reducing quarterly cash burn from the extreme levels seen in 2024 and late 2025, but it is still operating without revenue and remains dependent on external capital. The near-term story is one of survival and financing management rather than profitability.

07/17/26 01:04 AM ETAI Generated. May Contain Errors.

Rein Therapeutics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Rein Therapeutics' fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Rein Therapeutics' net income appears to be on an upward trend, with a most recent value of -$49.87 million in 2025, rising from -$12.88 million in 2015. The previous period was -$62.88 million in 2024. Check out Rein Therapeutics' forecast to explore projected trends and price targets.

Rein Therapeutics' total operating income in 2025 was -$50.63 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $50.63 million

Over the last 10 years, Rein Therapeutics' total revenue changed from $0.00 in 2015 to $0.00 in 2025, a change of 0.0%.

Rein Therapeutics' total liabilities were at $7.24 million at the end of 2025, a 7.2% decrease from 2024, and a 77.4% increase since 2016.

In the past 9 years, Rein Therapeutics' cash and equivalents has ranged from $3.22 million in 2025 to $20.72 million in 2016, and is currently $3.22 million as of their latest financial filing in 2025.

Over the last 10 years, Rein Therapeutics' book value per share changed from 0.00 in 2015 to -1.07 in 2025, a change of -106.9%.


Related Companies

Financial statements for NASDAQ:RNTX last updated on 7/16/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...
Investors Alley | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
Elon’s new "tollbooth"
The SpaceX IPO was valued at $1.75 trillion. But one analyst says fighting over those shares may be the wrong ...
Weiss Ratings | Sponsoredtc pixel